Abiomed Announces Publication Of PROTECT II Study In Circulation: Journal Of The American Heart Association

DANVERS, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that results from its PROTECT II study will be published in an upcoming print edition of Circulation, the journal of the American Heart Association. The study, "A Prospective Randomized Clinical Trial of Hemodynamic Support with Impella® 2.5 versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention: the PROTECT II Study," was accepted for publication on August 20, 2012 and published online on August 30, 2012 via the following link: http://m.circ.ahajournals.org/content/early/2012/08/30/CIRCULATIONAHA.112.098194

The PROTECT II study was a prospective multicenter randomized trial that was "designed to assess whether a high-risk percutaneous revascularization strategy with the support of the Impella 2.5 device would result in better outcomes than a revascularization strategy with intra aortic balloon pump (IABP) support."

"Today marks a very significant milestone in providing new clinical insight for cardiovascular disease patients considered too risky for conventional surgery. The PROTECT II publication in Circulation underscores the importance of this study's observations to the clinical community," said William W. O'Neill, M.D., principal investigator of the PROTECT II trial and medical director of the Center for Structural Heart Disease at Henry Ford Hospital in Detroit.

Study authors include William W. O'Neill, M.D.; Neal S. Kleiman, M.D.; Jeffrey Moses, M.D.; Jose P.S. Henriques, M.D., Ph. D.; Simon Dixon, MBChB; Joseph Massaro, Ph. D.; Igor Palacios, M.D.; Brijeshwar Maini, M.D.; Suresh Mulukutla, M.D.; Vladimir Dzavik, M.D.; Jeffrey Popma, M.D.; Pamela S. Douglas, M.D.; and Magnus Ohman, M.D.  Circulation has the highest ranking impact factor among journals in the Cardiac & Cardiovascular Systems category.

"PROTECT II is a landmark clinical trial and we are grateful to Dr. O'Neill and his colleagues for leading this study," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. "The peer-reviewed publication of PROTECT II in the esteemed Circulation journal is a notable achievement for Abiomed. Most importantly, we believe that this study will advance the treatment for patients with heart failure."

These data in PROTECT II have been collected, validated, and monitored by a third party academic research organization and the major adverse events (MAE) were assessed at 30 and 90 days. Additionally, all hospital charges were tracked by an independent health economic organization in coordination with the study.

If you liked this article you might like

Closing the Door on Abiomed

Capturing Profits on AIG

A Roundup of My Open Positions

Pumped Up About Abiomed Collar Play

Masimo's Stock Is a Great Buy Right Now